Evotec SE and its collaborators Toronto Innovation Acceleration Partners (“TIAP”) and AmorChem Therapeutics today announced a $ 1.75 m investment into a drug development project focused on a rare skin disease called Netherton Syndrome, that affects one in 200,000 newborns worldwide. Die Original-Meldung zu diesem Chemie Unternehmen finden Sie unter https://www.evotec.com/en/investor-relations/news/corporate-news/p/consortium-backs-successful-lab150-project-5937